Highlights From CROI

Share

Program Content

Activities

  • CROI Hot Topics
    Preview of Hot Topics at CROI 2019: My Picks
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 01, 2019

    Expires: February 28, 2020

  • New Data From CROI 2019
    Clinical Impact of New HIV Data From CROI 2019
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 22, 2019

    Expires: March 20, 2020

  • CROI 2019 US Webinar
    Key Studies Influencing My Practice Following CROI 2019
    Audio
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 01, 2019

    Expires: March 30, 2020

  • Long-Acting Injectable ART
    A New Chapter in ART? Implications of ATLAS and FLAIR Results From CROI 2019
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 10, 2019

    Expires: May 08, 2020

Activities

NICHD P1081
NICHD P1081: Improved Virologic Suppression at Delivery With RAL- vs EFV-Based ART in Pregnant Women With HIV Infection
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 07, 2019

Expires: March 05, 2020

DolPHIN-2
DolPHIN-2: More Rapid Virologic Suppression With DTG- vs EFV-Based ART Initiated in Late Pregnancy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 08, 2019

Expires: March 06, 2020

ATLAS
ATLAS: Week 48 Results From Phase III Study of Switching to Long-Acting Cabotegravir + Rilpivirine in Virologically Suppressed Patients With No Prior Virologic Failure
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 09, 2019

Expires: March 07, 2020

Study 380-1474
GS-US-380-1474: Switch to BIC/FTC/TAF Safely Maintains Virologic Suppression at Week 48 in Children and Adolescents With HIV Infection
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 11, 2019

Expires: March 09, 2020

DISCOVER
DISCOVER: Phase III Study of Emtricitabine/Tenofovir Alafenamide vs Emtricitabine/Tenofovir Disoproxil Fumarate for HIV PrEP
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 11, 2019

Expires: March 09, 2020

PrEP and Drug Resistance
Effects of PrEP on Drug Resistance and Acute HIV Infection in New York City Surveillance Population
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 11, 2019

Expires: March 09, 2020

FLAIR
FLAIR: Switch to Long-Acting CAB + RPV Following Oral Induction in ART-Naive Patients Noninferior to Continued DTG/ABC/3TC at Week 48
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 11, 2019

Expires: March 09, 2020

Opioid Overdose Deaths in HIV
Increased Deaths From Opioid Overdose Among Persons With HIV Infection, 2011-2015
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 11, 2019

Expires: March 09, 2020

HPTN 077
HPTN 077: No Significant Weight Gain at Week 41 With Long-Acting CAB vs PBO in HIV-Uninfected Persons at Low Risk for Infection
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 11, 2019

Expires: March 09, 2020

DAWNING
DAWNING: High Virologic Response Rates at Week 48 With DTG-Based ART Regardless of Baseline NRTI RAMs and Second-Line NRTI Use
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2019

Expires: March 11, 2020

Faculty

cover img faculity

W. David Hardy, MD

Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

David A. Wohl, MD

Associate Professor of Medicine
School of Medicine
Site Leader, AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director for HIV Services
North Carolina Department of Correction
Raleigh, North Carolina

Supporters

Supported by educational grants from

Gilead Text

Janssen

Merck Human Health HIV

ViiV Healthcare